CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt

First the setback, then the cuts. CytomX Therapeutics became the latest biotech to follow the rhythm of the industry late Wednesday, when it set out plans to reduce its headcount by 40% to extend its cash runway after its lead candidate failed to meet the bar for moving into phase 3.